MedTrace Logo

Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer

NCT00983424 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2013-09-16

No results posted yet for this study

Summary

The purpose of this research study is to evaluate the safety of therapy with nab-paclitaxel and CsA and if the addition of Cyclosporine A (CsA) to nab-paclitaxel helps stop cancer cells as well as or better than nab-paclitaxel alone.

Conditions

Interventions

DRUG

Cyclosporins

dose escalation, administered orally twice a day

DRUG

nab-paclitaxel

100 mg/m2 IV days 1, 8 and 15

Sponsors & Collaborators

Principal Investigators

  • William Gradishar, MD · Northwestern University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00983424 on ClinicalTrials.gov